Forum Bourse DBV TECHNOLOGIES - 08/03/2021 09:26:42 - On va voir si on a du nouveau du côté de l'ema :) DBV TECHNOLOGIES S.A. : Actualités, news et informations action DBV TECHNOLOGIES S.A. | DBV | FR0010417345 | Euronext Paris Click here to find out more about our partners. Our investigational therapeutic treatment is based on epicutaneous immunotherapy, or EPIT™. Suivez toute l'actualité de DBV TECHNOLOGIES, les communiqués, analyses et rapports financiers, les enjeux économiques pour cette valeur côtée à la Bourse de Paris, et bien plus encore ! Clinical|Corporate|Product Candidates|Science, Clinical|Conferences|Product Candidates|Science, Clinical|Corporate|Partnership|Product Candidates|Science, Clinical|Partnership|Product Candidates|Science. A high-level overview of DBV Technologies S.A. (DBVT) stock. Real time DBV Technologies (DBVT) stock price quote, stock graph, news & analysis. DBV Technologies News < Zurück < Zurück. Find the latest news headlines from DBV Technologies S.A. American Depositary Shares (DBVT) at Nasdaq.com. DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter of 2021. DBV Technologies (DBV) News Headlines. Share Price & News. DBV TECHNOLOGIES S.A. (Exact name of registrant as specified in its charter and translation of registrant's name into English) France (Jurisdiction of incorporation or organization) 177-181 avenue Pierre Brossolette 92120 Montrouge France (Address of … DBV TECHNOLOGIES News: This is the News-site for the company DBV TECHNOLOGIES on Markets Insider DBV Technologies (DBVT) Set to Announce Quarterly Earnings on Thursday americanbankingnews.com - March 1 at 10:12 AM: DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021 finance.yahoo.com - March 1 at 7:25 AM: DBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI 2021 Congress How has DBV Technologies's share price performed over time and what events caused price changes? Several research firms have issued reports on DBVT. Ou est ce juste l'odeur de la poudre spéculative avant explosion ? Zacks Investment Research lowered DBV Technologies from […] von 12. !, ce post n'est pas injurieux, n'incite ni à l'achat ni à la vente. The quarterly financial statements were approved by the Board of Directors on April 30, 2021. DBV Technologies Statutory auditors' report on the financial statements December 31, 2020 We attest the fair presentation and the consistency with the financial statements of the information relating to payment deadlines mentioned in Article D.441-6 of the French Commercial Code (Code de commerce).Information relating to corporate governance DBV Technologies' Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma seekingalpha.com - July 13 at 8:18 PM DBV Tech's Viaskin Peanut shows benefit in … Find out more about how we use your information in our Privacy Policy and Cookie Policy. 05/03/21 Achilles Therapeutics appoints O'Neill to board of directors, Velders to SAB 03/12/21 DBV jumps 14% to $5.98 after 2020 results, business update The stock had previously closed at $6.01, but opened at $6.38. Stable Share Price: DBV is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 8% a week. DBV Technologies S.A. (NASDAQ:DBVT)’s share price gapped up before the market opened on Friday . Forum Bourse DBV TECHNOLOGIES - 18/02/2021 22:25:46 - Il y a 54 929 187 actions au capital : C'est la dernière news :) Find the latest news headlines from DBV Technologies S.A. American Depositary Shares (DBVT) at Nasdaq.com. Latest Share Price and Events. Tous les articles Bourse et finance consacrés au spécialiste de la désensibilisation aux allergies DBV Technologies [FR0010417345 DBV] Intraday DBV Technologies Chart. DBV Technologies therapies are investigational and not FDA approved. Ne pas l'effacer. DBV technologies pourrait se faire griller la politesse aux États-Unis La biotech française a obtenu l’acceptation par la Food and Drug Administration américaine du dépôt de sa demande de licence pour Viaskin Peanut, mais l‘allongement des délais pourrait favoriser la concurrence. DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021 Download PDF (145 KB) 2021: 05/03/2021 - 7:30 am. Free real-time prices, trades, and chat. Find the latest DBV Technologies S.A. (DBVT) stock quote, history, news and other vital information to help you with your stock trading and investing. Forum Bourse DBV TECHNOLOGIES - 24/03/2021 09:30:22 - Chaque jour je reçois les news letters de la FDA, cela concerne les médicaments validés du CDER, les produits et outils médicaux. Free real-time prices, trades, and chat. Forum Bourse DBV TECHNOLOGIES - 06/01/2021 16:42:11 - Y a t il une explication a cette hausse journalière ? Information about your device and Internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. Get the latest news and real-time alerts from DBV Technologies S.A. (DBVT) stock at Seeking Alpha. DBV Technologies is developing Viaskin ®, an investigational proprietary technology platform with broad potential applications in immunotherapy.Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. DBV DBV Techno.. Register now to watch these stocks streaming on the ADVFN Monitor. DBV Technologies shares last traded at $6.48, with a volume of 716 shares traded. Real time DBV Technologies (DBVT) stock price quote, stock graph, news & analysis. DBV Technologies s’envole après de bonnes nouvelles sur son traitement phare. By clicking "Accept all", you agree that Verizon Media and our partners will store and/or access information on your device through the use of cookies and similar technologies and process your personal data to display personalised ads and content, for ad and content measurement, audience insights and product development. DBV technologies a été fondé par des pédiatres et entrepreneurs convaincus que les allergies alimentaires devraient un jour être traitées sans risque et de manière efficace. Get the latest DBV Technologies S.A. (DBVT) stock news and headlines to help you in your trading and investing decisions. DBVT Stock: DBV Technologies Soars on Big Peanut Allergy Patch News Jan. 15, 2021 at 11:23 a.m. DBV Technologies news and DBVT price. DBV Technologies : recule après les résultats, avis d'analystes divergents 03/05 DBV Technologies : la trésorerie et les équivalents de trésorerie au 31 mars s'élevaient à 152,5 M$ DBVT DBV Technologies. Your Recent History EU. All rights reserved. Weiter > Weiter > < Zurück < Zurück. DBV Technologies news and DBVT price. DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. © 2018 DBV Technologies. Free real-time prices, trades, and chat. Consultez la liste des actualités Bourse de l'action DBV Technologies. 1 Year DBV Technologies Chart. You can select 'Manage settings' for more information and to manage your choices. ET on InvestorPlace.com DBV Technologies … DBV Technologies Reports Q1 2021 Financial Results Download PDF (276 KB) 2021: 04/29/2021 - 7:30 am. (Boursier.com) — DBV Technologies trébuche de 3,7% à 10,8 euros après son point trimestriel. 10/16/2019 - 12:30 pm | Corporate | Finance, 04/03/2019 - 10:10 pm | Corporate | Finance, 12/06/2018 - 8:00 pm | Corporate | Finance, 11/07/2018 - 6:30 pm | Corporate | Finance, Procedures for Obtaining Preparatory Documents for the General MeetingDownload PDF (461 KB), Information regarding the total number of voting rights and total number of shares of the Company on May 18th, 2018
Advertise Here. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Get the latest news and real-time alerts from DBV Technologies S.A. (DBVT) stock at Seeking Alpha. Suivez toute l'actualité de DBV TECHNOLOGIES, les communiqués, analyses et rapports financiers, les enjeux économiques pour cette valeur côtée à la Bourse de Paris, et bien plus encore ! You can change your choices at any time by visiting Your Privacy Controls. DBV Technologies news and DBV price. Real-Time news about DBV Technologies (Euronext): 0 recent articles. Le cours de l'action DBV TECHNOLOGIES DBV en temps réel sur Boursorama : historique de la cotation sur Euronext Paris, graphique, actualités, consensus des analystes et informations boursières Weiter > Weiter > 12.03.21 - GlobeNewswire Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021. (Boursier.com) — DBV Technologies trébuche de 3,7% à 10,8 euros après son point trimestriel. DBV TECHNOLOGIES News: This is the News-site for the company DBV TECHNOLOGIES on Markets Insider DBV Technologies, les Hôpitaux Universitaires de Genève et BioNet-Asia ont présenté les données additionnelles d’une étude de phase I sur l’utilisation d’un patch épicutané expérimental en vaccination de rappel contre la coqueluche lors de l’European Congress of Immunology Télécharger le PDF (443 Ko) 2018: Scientifique von 12. More DBV Technologies News. La biotech déposera «durant le second semestre 2018» une demande de mise sur le marché auprès de l’agence américaine du médicament (FDA) pour son produit phare contre l’allergie à … DBV TECHNOLOGIES : News, information and stories for DBV TECHNOLOGIES | Euronext Paris: DBV | Euronext Paris Figaro Bourse. Forum Bourse DBV TECHNOLOGIES - 10/05/2021 08:20:41 - Deuxième effacement ! Download PDF (256 KB), 05/29/2018 - 7:30 am | Medical Congresses, 05/08/2018 - 7:30 am | Medical Congresses, 03/16/2018 - 9:30 pm | Corporate | Finance, 10/03/2017 - 5:58 pm | Corporate | Finance, 05/12/2017 - 5:29 pm | Corporate | Finance, 05/02/2017 - 5:32 pm | Conferences | Finance, 03/30/2017 - 9:32 pm | Clinical | Corporate, 03/22/2017 - 11:30 pm | Corporate | Finance, 03/10/2017 - 7:30 am | Clinical | Product Candidates, 03/05/2017 - 9:45 pm | Clinical | Conferences, 02/10/2017 - 10:41 pm | Conferences | Corporate | Science, 02/03/2017 - 7:30 am | Clinical | Product Candidates, 01/09/2017 - 7:30 am | Corporate | Finance, 12/07/2016 - 10:57 am | Corporate | Finance, 11/17/2016 - 7:30 am | Clinical | Product Candidates, 11/16/2016 - 10:57 am | Corporate | Finance, 11/08/2016 - 3:01 pm | Clinical | Product Candidates, 10/26/2016 - 3:04 pm | Clinical | Product Candidates, 10/24/2016 - 3:05 pm | Clinical | Product Candidates, 10/17/2016 - 3:06 pm | Corporate | Finance, 09/21/2016 - 3:07 pm | Product Candidates, 09/06/2016 - 3:08 pm | Clinical | Partnership, 06/15/2016 - 3:17 pm | Product Candidates | Science, 06/01/2016 - 3:20 pm | Conferences | Science, 03/06/2016 - 3:29 pm | Product Candidates, 03/04/2016 - 3:30 pm | Product Candidates, 02/25/2016 - 3:32 pm | Product Candidates, 02/10/2016 - 3:34 pm | Conferences | Finance, 12/07/2015 - 7:00 pm | Clinical | Product Candidates, 11/18/2015 - 7:01 pm | Clinical | Science, 11/03/2015 - 7:04 pm | Corporate | Finance, 10/14/2015 - 7:07 pm | Clinical | Product Candidates, 10/05/2015 - 7:08 pm | Clinical | Product Candidates, 09/11/2015 - 7:09 pm | Corporate | Finance, 09/03/2015 - 7:11 pm | Conferences | Corporate, 08/26/2015 - 10:17 pm | Conferences | Finance, 07/28/2015 - 10:18 pm | Corporate | Finance, 07/27/2015 - 7:13 pm | Corporate | Finance, 07/17/2015 - 10:19 pm | Clinical | Product Candidates, 07/15/2015 - 7:15 pm | Corporate | Finance, 07/14/2015 - 7:16 pm | Corporate | Finance, 07/02/2015 - 11:30 pm | Corporate | Finance, 07/02/2015 - 6:30 pm | Corporate | Finance, 06/08/2015 - 7:25 pm | Conferences | Science, 06/04/2015 - 7:27 pm | Corporate | Science, 06/02/2015 - 7:28 pm | Conferences | Finance, 05/05/2015 - 7:31 pm | Conferences | Corporate | Finance, 04/30/2015 - 7:32 pm | Corporate | Finance, 04/29/2015 - 7:34 pm | Corporate | Finance, 04/28/2015 - 7:47 pm | Corporate | Finance, 04/15/2015 - 7:49 pm | Conferences | Corporate | Science, 04/09/2015 - 7:50 pm | Corporate | Product Candidates, 03/25/2015 - 7:51 pm | Corporate | Finance, 03/06/2015 - 7:53 pm | Conferences | Finance, 02/24/2015 - 7:54 pm | Conferences | Science, 02/13/2015 - 7:56 pm | Corporate | Science, 02/03/2015 - 7:57 pm | Conferences | Finance, 02/03/2015 - 6:30 pm | Conferences | Science, 01/29/2015 - 7:30 am | Corporate | Finance, 01/14/2015 - 6:00 pm | Corporate | Finance, 11/20/2014 - 10:09 pm | Clinical | Product Candidates, 10/23/2014 - 10:10 pm | Corporate | Finance, Over-allotment option exercised in fullDownload PDF (110 KB), 10/22/2014 - 10:11 pm | Corporate | Finance, 10/20/2014 - 10:13 pm | Corporate | Finance, 10/14/2014 - 10:14 pm | Conferences | Finance, 09/22/2014 - 10:15 pm | Clinical | Science, 07/17/2014 - 10:20 pm | Clinical | Partnership | Product Candidates, 06/16/2014 - 10:21 pm | Corporate | Finance, 06/10/2014 - 11:35 pm | Conferences | Science, 05/13/2014 - 11:40 pm | Clinical | Partnership | Product Candidates, 05/12/2014 - 11:43 pm | Corporate | Finance, 04/17/2014 - 11:44 pm | Corporate | Finance, 04/16/2014 - 11:45 pm | Clinical | Conferences | Product Candidates, CFA 2014 - Clinical AbstractDownload PDF (142 KB), 04/16/2014 - 6:10 am | Clinical | Conferences | Product Candidates, DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin® at the French Congress of AllergyDownload PDF (142 KB), 04/15/2014 - 11:46 pm | Corporate | Finance, 04/09/2014 - 11:48 pm | Corporate | Partnership | Science, 03/25/2014 - 11:49 pm | Conferences | Science, 03/17/2014 - 11:51 pm | Clinical | Corporate | Finance, 03/04/2014 - 11:52 pm | Conferences | Science, 02/18/2014 - 11:53 pm | Corporate | Partnership | Science, 01/30/2014 - 11:54 pm | Corporate | Finance, 12/17/2013 - 3:25 pm | Clinical | Corporate | Product Candidates | Science, 12/13/2013 - 3:26 pm | Clinical | Conferences | Product Candidates | Science, 11/26/2013 - 3:28 pm | Corporate | Partnership | Science, 11/14/2013 - 3:29 pm | Corporate | Finance, 10/24/2013 - 3:30 pm | Clinical | Partnership | Product Candidates, 10/22/2013 - 3:31 pm | Corporate | Partnership | Science, 10/18/2013 - 3:34 pm | Clinical | Corporate | Partnership | Product Candidates | Science, 10/15/2013 - 3:35 pm | Clinical | Corporate | Finance, 09/04/2013 - 3:36 pm | Clinical | Product Candidates, 07/08/2013 - 3:37 pm | Clinical | Product Candidates, 06/28/2013 - 3:38 pm | Conferences | Science, 06/20/2013 - 3:39 pm | Clinical | Partnership | Product Candidates, 05/16/2013 - 3:40 pm | Clinical | Partnership | Product Candidates | Science, 05/07/2013 - 3:41 pm | Corporate | Partnership | Science, 04/25/2013 - 3:42 pm | Corporate | Finance, 03/05/2013 - 3:43 pm | Corporate | Finance | Partnership, 03/04/2013 - 3:44 pm | Corporate | Finance | Science, 01/31/2013 - 3:45 pm | Clinical | Corporate | Finance | Science, 01/15/2013 - 3:46 pm | Corporate | Partnership | Science, 11/14/2012 - 5:20 pm | Clinical | Corporate | Product Candidates | Science, 10/16/2012 - 9:46 am | Corporate | Science, 10/15/2012 - 4:00 pm | Corporate | Finance, 08/02/2012 - 5:42 pm | Clinical | Corporate | Product Candidates, 07/26/2012 - 9:19 am | Clinical | Corporate | Science, 07/19/2012 - 5:30 pm | Corporate | Science, 06/18/2012 - 11:15 am | Clinical | Conferences | Product Candidates, 06/18/2012 - 11:07 am | Clinical | Product Candidates, 05/31/2012 - 11:20 am | Corporate | Science, 05/15/2012 - 10:53 am | Clinical | Finance | Science, 03/28/2012 - 10:28 am | Corporate | Finance, 02/28/2012 - 9:32 am | Clinical | Product Candidates | Science, 01/31/2012 - 10:05 am | Corporate | Finance, 12/06/2011 - 10:26 am | Corporate | Finance, 06/08/2011 - 9:09 am | Clinical | Science, 01/18/2011 - 10:47 am | Corporate | Science, 01/08/2011 - 9:58 am | Corporate | Science, 01/05/2011 - 10:57 am | Corporate | Finance, 09/23/2010 - 9:52 am | Corporate | Finance | Product Candidates, 09/01/2010 - 10:00 am | Clinical | Product Candidates, 07/06/2010 - 10:02 am | Clinical | Product Candidates, 06/14/2010 - 10:05 am | Corporate | Science, 04/15/2009 - 12:45 am | Corporate | Partnership, 01/22/2009 - 11:20 am | Corporate | Finance, 11/13/2007 - 11:23 am | Corporate | Science, 01/23/2006 - 11:25 am | Corporate | Finance, Clinical | Partnership | Product Candidates, Clinical | Conferences | Product Candidates, Clinical | Corporate | Product Candidates | Science, Clinical | Conferences | Product Candidates | Science, Clinical | Corporate | Partnership | Product Candidates | Science, Clinical | Partnership | Product Candidates | Science, Clinical | Corporate | Product Candidates. With this mission driving our commitment to the advancement of treatments in this field, we are investigating a potential new class of immunotherapy that aims to activate the immune system of …